Leveraging data, digitalisation, and artificial intelligence: A new era for medicines regulation

The evolution of medicine is no longer just about molecules; it’s about the ability to integrate technology and data to transform health on a global scale. In this piece for pharmaphorum, Roberto Ascione explores how the regulatory landscape must evolve to become an enabler of innovation rather than a bottleneck.

The Vision: From Static to Dynamic Regulation

The traditional “point-in-time” approval model is becoming obsolete. With the rise of Digital Therapeutics (DTx) and Software as a Medical Device (SaMD), compliance must shift toward a continuous, data-driven process.

The Pillars of Digital Regulatory Transformation

The future of regulation is built on three fundamental drivers:

• Real-World Data (RWD) Explosion: Moving beyond limited clinical trial data to a constant stream of Real-World Evidence (RWE) to monitor safety and efficacy in real-time.
• AI as a Core Component: AI is no longer just a research tool but a fundamental part of “new medicine” requiring algorithmic validation, transparency, and bias mitigation.
• Technological Convergence: The blurring lines between biotechnology, pharmacology, and software, giving rise to what we can define as “biological software.”